NCT05077683View on ClinicalTrials.gov

Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF

PHASE3CompletedINTERVENTIONAL
Enrollment

560

Participants

Timeline

Start Date

October 10, 2021

Primary Completion Date

March 10, 2023

Study Completion Date

February 9, 2024

Conditions
Myocardial Infarction, AcuteLeft Ventricular Thrombus
Interventions
DRUG

Rivaroxaban 2.5 MG [Xarelto]

Experimental group: usual DAPT strategy (aspirin (≤100mg per day), clopidogrel (75mg per day) or ticagrelor (90mg twice daily)) + rivaroxaban 2.5mg twice daily.

DRUG

DAPT strategy

usual DAPT strategy (aspirin (≤100mg per day), clopidogrel (75mg per day) or ticagrelor (90mg twice daily)) +

Trial Locations (1)

Unknown

HEGP, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT05077683 - Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF | Biotech Hunter | Biotech Hunter